All In Biotech

NDA 208010 · Eirgen

Rayaldee

Calcifediol · Oral

Last checked: Nov 19, 2026Latest source record: Jan 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Jun 17, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

61

19 Phase 3, 3 recruiting

FAERS reports

2,547

2,435 serious, 384 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 19, 2024.

RAYALDEE is a vitamin D 3 analog indicated for the treatment of secondary hyperparathyroidism in adult patients with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Limitations of Use RAYALDEE is not indicated for the treatment of secondary hyperparathyroidism in patients with stage 5 chronic kidney disease or in patients with end-stage renal disease on dialysis. RAYALDEE is a vitamin D 3 analog indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. ( 1 ) Limitations of Use: RAYALDEE is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis. ( 1 )

Mechanism: Calcifediol (25-hydroxyvitamin D 3 ) is a prohormone of the active form of vitamin D 3 , calcitriol (1,25‑dihydroxyvitamin D 3 ). Calcifediol is converted to calcitriol by cytochrome P450 27B1 (CYP27B1), also called 1-alpha hydroxylase, primarily in the kidney. Calcitriol binds to the vitamin D receptor in target tissues and activates vitamin D responsive pathways that result in increased intestinal absorption of calcium and phosphorus and reduced parathyroid hormone synthesis.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • RAYALDEE · CALCIFEDIOL 0.03MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Calcifediol" as an intervention, any sponsor and status, largest first.

All 61 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death219
  • off label use141
  • drug interaction131
  • acute kidney injury127
  • anaemia78
  • nausea76
  • dyspnoea74
  • pneumonia70
  • pyrexia70
  • covid-1964
  • hypotension63
  • diarrhoea62

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
20053
20063
20071
20083
20095
201012
20112
201210
20137
20149
201511
201615
201740
201879
2019122
2020158
2021166
2022267
2023392
2024494
2025358
2026384

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rayaldee (Calcifediol)

2024 spending

$42.8M

Beneficiaries

5,248

31,494 claims

Per beneficiary

$8,164

$40.58 per unit

View as table
YearSpending
2020$61,315,676
2021$39,639,508
2022$36,135,698
2023$41,491,958
2024$42,845,344

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 94 on PubMed

Sponsor: Eirgen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.